| Literature DB >> 28345541 |
Duo Xu1, Ruo-Chi Zhao2, Wen-Hui Gao3, Han-Bin Cui2.
Abstract
BACKGROUND: Myocarditis is an inflammatory disease of the myocardium that may lead to cardiac death in some patients. However, little is known about the predictors of in-hospital mortality in patients with suspected myocarditis. Thus, the aim of this study was to identify the independent risk factors for in-hospital mortality in patients with suspected myocarditis by establishing a risk prediction model.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28345541 PMCID: PMC5381311 DOI: 10.4103/0366-6999.202747
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Figure 1The comparison of in-hospital days between survival and nonsurvival groups. It showed that 69.2% of patients in the nonsurvival group were discharged from the hospital within 3 days due to death whereas 6.6% of patients in the survival group were discharged from the hospital within 3 days due to recovery.
Baseline characteristics of patients with suspected myocarditis (n = 403)
| Variables | Values |
|---|---|
| Age (years), mean ± SD | 33.0 ± 13.7 |
| Sex (male), | 238 (59.1) |
| Smoking habit*, | 96 (23.8) |
| Underlying diseases, | |
| Hypertension | 44 (10.9) |
| Diabetes | 5 (1.2) |
| Stroke | 0 |
| Coronary artery disease | 17 (4.2) |
| Congenital heart disease | 4 (1.0) |
| Chronic pulmonary disease | 8 (2.0) |
| Symptom†, | |
| Syncope | 65 (16.1) |
| Chest pain | 92 (22.8) |
| Chest distress | 245 (60.8) |
| Palpitation | 76 (18.9) |
| The NYHA classification, | |
| Grade 1 | 167 (41.4) |
| Grade 2 | 121 (30.0) |
| Grade 3 | 28 (6.9) |
| Grade 4 | 87 (21.7) |
| Used medicine, | |
| Glucocorticoid‡ | 182 (45.2) |
| β-blocker§ | 134 (33.3) |
*Smoking in the past year; †The presentation on admission; ‡Methylprednisolone or dexamethasone; §Metoprolol or bisoprolol. SD: Standard deviation; NYHA: New York Heart Association classification.
Potential risk factors in survivors and nonsurvivors with suspected myocarditis
| Variables | Survivors ( | Nonsurvivors ( | Statistics | |
|---|---|---|---|---|
| Age (≥50 years), | 90 (24.7) | 30 (76.9) | 45.90* | <0.001 |
| Male, | 207 (56.9) | 31 (79.5) | 7.45* | 0.006 |
| BMI (kg/m2), mean ± SD | 22.3 ± 3.2 | 22.7 ± 2.4 | 0.68† | 0.495 |
| Smoking habit, | 80 (22) | 16 (41) | 7.04* | 0.008 |
| Underlying diseases, | ||||
| Hypertension | 36 (9.9) | 8 (20.5) | 3.07* | 0.080 |
| Diabetes | 4 (1.1) | 1 (2.6) | 0.62* | 0.433 |
| Stroke | 0 | 0 | – | – |
| Coronary artery disease, | 13 (3.6) | 4 (10.3) | 2.42* | 0.120 |
| Congenital heart disease, | 4 (1.1) | 0 | – | – |
| Chronic pulmonary disease, | 8 (2.2) | 0 | – | – |
| Symptom on admission, | ||||
| Syncope | 53 (14.6) | 12 (30.8) | 6.41* | 0.011 |
| Chest pain | 80 (22) | 12 (30.8) | 0.79* | 0.373 |
| Chest distress | 217 (59.6) | 28 (71.8) | 2.192* | 0.139 |
| Palpitation | 65 (17.9) | 11 (28.2) | 2.47* | 0.116 |
| Digestive symptom, | 56 (15.4) | 15 (38.5) | 12.93* | <0.001 |
| Abnormal heart rate, | 152 (41.8) | 19 (48.7) | 0.61* | 0.404 |
| Fever, | 82 (22.5) | 12 (30.8) | 1.34* | 0.247 |
| Blood glucose (mmol/L), mean ± SD | 6.1 ± 2.3 | 7.7 ± 4.0 | 3.76† | 0.001 |
| Systolic pressure (mmHg), mean ± SD | 114.6 ± 19.1 | 106.8 ± 26.5 | −2.34† | 0.020 |
| Diastolic pressure (mmHg), mean ± SD | 71.7 ± 13.7 | 70.6 ± 19.3 | −0.47† | 0.636 |
| Blood examination | ||||
| WBC (×109/L), mean ± SD | 9.5 ± 4.5 | 10.2 ± 6.4 | 0.68† | 0.498 |
| Neutrophil (×109/L), mean ± SD | 7.1 ± 4.6 | 8.3 ± 5.8 | 1.44† | 0.150 |
| Red blood cell (×1012/L), mean ± SD | 4.3 ± 0.5 | 4.5 ± 0.3 | 2.58† | 0.012 |
| Hematocrit (%), mean ± SD | 38.2 ± 5.1 | 40.4 ± 3.9 | 2.63† | 0.009 |
| MCV (fl), mean ± SD | 89.9 ± 5.5 | 90.4 ± 4.4 | 0.56† | 0.574 |
| Platelet count (×109/L), mean ± SD | 199.7 ± 51.3 | 154.3 ± 78.0 | −3.56† | 0.001 |
| C-reactive protein (mg/L), median (IQR) | 17.4 (2.8–31.9) | 55.3 (30.9–99.9) | –5.11‡ | <0.001 |
| ALT (U/L), median (IQR) | 37.5 (19.0–67.0) | 1235.0 (93.0–1412.7) | –6.29‡ | <0.001 |
| AST (U/L), median (IQR) | 37.0 (22.0–92.8) | 609.5 (150.3–1981.5) | –6.44‡ | <0.001 |
| CK (U/L), median (IQR) | 166.0 (60.0–495.0) | 2659.7 (1309.0–4516.0) | −6.94‡ | <0.001 |
| CKMB (U/L), median (IQR) | 24.0 (12.0–47.0) | 164.2 (83.0–391.0) | −6.93‡ | <0.001 |
| LDH (U/L), median (IQR) | 240.0 (171.0–405.0) | 1967.2 (1415.0–3045.0) | −7.35‡ | <0.001 |
| NT-proBNP (pg/ml), median (IQR) | 2945.7 (234.0–5771.5) | 9850.4 (7060.0–21,665.0) | −7.00‡ | <0.001 |
| D-dime (mg/L), median (IQR) | 848.2 (198.0–1118.0) | 1092.0 (791.0–2173.9) | −6.72‡ | <0.001 |
| Coxsackie virus B (+), | 5 (1.4) | 0 | – | – |
| Arrhythmia, | ||||
| AVB III | 38 (10.4) | 7 (17.9) | 0.34* | 0.561 |
| VT | 35 (9.6) | 22 (56.4) | 63.52* | <0.001 |
| SVT | 16 (4.4) | 0 | – | – |
| Electrocardiogram | ||||
| ST-segment elevation, | 49 (13.5) | 23 (59) | 49.73* | <0.001 |
| Q-wave, | 49 (13.5) | 11 (28.2) | 6.04* | 0.014 |
| QTc interval delayed, | 65 (17.9) | 19 (48.7) | 20.33* | <0.001 |
| QRS duration (ms), mean ± SD | 96.9 ± 25.0 | 102.6 ± 40.5 | 0.86* | 0.393 |
| Cardiac ultrasound | ||||
| LVEF (%), mean ± SD | 63.9 ± 9.7 | 50.5 ± 7.6 | −6.08† | <0.001 |
| Atrium enlargement, | 28 (7.7) | 0 | – | – |
| LVFS <0.25, | 72 (19.8) | 19 (48.7) | 16.87* | <0.001 |
| Chest CT, | ||||
| Podoid enlargement | 74 (20.3) | 8 (20.5) | 0.001* | 0.978 |
| Pulmonary edema | 64 (17.6) | 16 (41) | 12.17* | <0.001 |
| Ccr <60 ml/min, | 49 (13.5) | 32 (82.1) | 103.19* | <0.001 |
| Thyroid dysfunction, | 78 (21.4) | 8 (20.5) | 0.018* | 0.894 |
| cTnT ≥50 µg/L, | 28 (7.7) | 20 (51.3) | 63.79* | <0.001 |
| Used medicine, | ||||
| Glucocorticoid | 159 (43.7) | 23 (59.0) | 3.33* | 0.068 |
| β-blocker | 126 (34.6) | 8 (20.5) | 3.16* | 0.076 |
| NYHA ≥3, | 85 (23.4) | 30 (76.9) | 49.57* | <0.001 |
*The statistics were calculated using Chi-square test, continuity correction Chi-square test, or Fisher's exact test, as appropriate; †The statistics were calculated using Student's t-test or separate variance estimation t-test, as appropriate; ‡The statistics were calculated using Mann-Whitney U test. All the data were from the results of the first tests after admission. –: No data. SD: Standard deviation; IQR: interquartile range; WBC: White blood cell; MCV: Mean corpuscular volume; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CK: Creatine kinase; CKMB: Creatine kinase MB; LDH: Lactate dehydrogenase; AVB: Auriculo-ventricular block; SVT: Supraventricular tachycardia; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening; NYHA: New York Heart Association classification; BMI: Body mass index; NT-proBNP: N-terminal pro-brain natriuretic peptide; cTnT: Cardiac troponin T; Ccr: Creatinine clearance rate; VT: Ventricular tachycardia; CT: Computed tomography.
Results of test to multicollinearity in screened risk factors
| Variables | TOL | VIP |
|---|---|---|
| Age (≥50 years) | 0.604 | 1.656 |
| Male | 0.526 | 1.902 |
| Smoking habit | 0.503 | 1.988 |
| Hypertension | 0.500 | 1.999 |
| Syncope | 0.584 | 1.713 |
| Digestive symptom | 0.670 | 1.492 |
| VT | 0.468 | 2.138 |
| ST-segment elevation | 0.400 | 2.501 |
| Q-wave | 0.512 | 1.952 |
| QTc interval delayed | 0.407 | 2.459 |
| LVFS <0.25 | 0.747 | 1.338 |
| Pulmonary edema | 0.621 | 1.610 |
| Ccr <60 ml/min | 0.553 | 1.808 |
| cTnT ≥50 µg/L | 0.375 | 2.666 |
| NYHA ≥3 | 0.377 | 2.651 |
| Blood glucose | 0.382 | 2.617 |
| Systolic pressure | 0.594 | 1.684 |
| LVEF | 0.590 | 1.695 |
| Hematocrit | 0.734 | 1.362 |
| Platelet count | 0.487 | 2.055 |
| C-reactive protein | 0.554 | 1.805 |
| AST* | 0.189 | 5.289 |
| ALT | 0.211 | 4.738 |
| CK | 0.240 | 4.172 |
| CKMB | 0.222 | 4.510 |
| LDH* | 0.156 | 6.402 |
| NT-proBNP | 0.299 | 3.342 |
| D-dimer* | 0.160 | 6.231 |
TOL and VIP were the two parameters for diagnosing multicollinearity (VIP is calculated as follows: VIP = 1/[1−Ri2], and TOL is calculated as follows: TOL = 1 − Ri2, where Ri2 is the coefficient of association of each variable regressed on the remaining predictor variables). A TOL ≤0.2 or VIP ≥5 was indicative of the potential existence of multicollinearity between a particular variable and the remaining variables. *According to the rule, AST, LDH, and D-dimer should be excluded from subsequent analyses. TOL: Tolerance; VIP: Variance inflation factor; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CK: Creatine kinase; CKMB: Creatine kinase MB; LDH: Lactate dehydrogenase; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening; NYHA: New York Heart Association classification; VT: Ventricular tachycardia; cTnT: Cardiac troponin T; Ccr: Creatinine clearance rate; NT-proBNP: N-terminal pro-brain natriuretic peptide.
Logistic regression analysis for independent risk factors of in-hospital mortality
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Age (≥50 years)* | 20.71 (7.86–54.53) | <0.001 | 7.43 (2.18–25.34) | 0.001 |
| Male* | 5.94 (3.32–8.57) | <0.001 | 3.48 (0.99–12.20) | 0.052 |
| Smoking habit | 2.47 (1.25–4.90) | 0.010 | – | – |
| Hypertension | 2.35 (1.01–5.50) | 0.049 | – | – |
| Syncope | 2.61 (1.25–5.47) | 0.011 | – | – |
| Digestive symptom | 3.44 (1.70–6.96) | 0.001 | – | – |
| VT* | 12.17 (5.91–25.05) | <0.001 | 6.89 (1.86–25.44) | 0.004 |
| ST-segment elevation | 9.24 (4.56–18.71) | <0.001 | – | – |
| Q-wave | 2.53 (1.18–5.40) | 0.017 | – | – |
| QTc interval delayed | 4.38 (2.21–8.65) | <0.001 | – | – |
| LVFS <0.25 | 3.85 (1.95–7.60) | <0.001 | – | – |
| Pulmonary edema | 3.26 (1.63–6.52) | 0.001 | – | – |
| Ccr <60 ml/min* | 29.39 (12.30–70.25) | <0.001 | 19.94 (5.66–70.26) | <0.001 |
| cTnT ≥50 µg/L* | 19.56 (8.96–42.73) | <0.001 | 3.10 (0.91–10.62) | 0.072 |
| NYHA ≥3* | 10.94 (5.00–24.00) | <0.001 | 4.03 (1.13–14.32) | 0.031 |
| Blood glucose | 1.18 (1.07–1.30) | 0.001 | – | – |
| Systolic pressure | 0.51 (0.28–0.94) | 0.031 | – | – |
| LVEF | 0.90 (0.87–0.93) | <0.001 | – | – |
| Hematocrit | 1.74 (0.94–3.20) | 0.077 | – | – |
| Platelet count | 0.99 (0.98–0.99) | <0.001 | – | – |
| C-reactive protein | 1.01 (1.00–1.01) | <0.001 | – | – |
| ALT | 1.00 (1.00–1.00) | <0.001 | – | – |
| CK | 1.00 (1.00–1.00) | <0.001 | – | – |
| CKMB | 1.01 (1.01–1.01) | <0.001 | – | – |
| NT-proBNP | 1.00 (1.00–1.00) | <0.001 | – | – |
*After univariate and multivariate logistic regression analyses, the final prediction model including six variables was established including a Ccr <60 ml/min, an age ≥50 years, VT, an NYHA classification ≥3, male gender, and a cTnT level ≥50 μg/L. OR: Odds ratio; CI: Confidence interval; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CK: Creatine kinase; CKMB: Creatine kinase MB; LDH: Lactate dehydrogenase; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening; NYHA: New York Heart Association classification; VT: Ventricular tachycardia; cTnT: Cardiac troponin T; Ccr: Creatinine clearance rate; NT-proBNP: N-terminal pro-brain natriuretic peptide. –: Not applicable.
Figure 2Receiver operating characteristic curve of the prediction model for in-hospital mortality in patients with suspected myocarditis. The area under the receiver operating characteristic curve (AUC) was 0.96 (standard error = 0.015, 95% confidence interval: 0.93–0.99). It shows that the sensitivity and specificity of the prediction model are adequate in statistics.